US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% SNDK $1,719.99 ▲+0.00% NVDA $233.95 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% WDC $415.29 ▲+0.00% MSTR $160.01 ▲+0.00%
FinancialContent

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

0.9303 UNCHANGED
Delayed Quote Updated: 8:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lineage Cell Therapeutics, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
5 Analysts Assess Lineage Cell Therapeutics: What You Need To Know ↗
 
Via Benzinga
News headline image
Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
A Peek at Lineage Cell Therapeutics's Future Earnings ↗
 
Via Benzinga
News headline image
Beyond The Numbers: 7 Analysts Discuss Lineage Cell Therapeutics Stock ↗
 
Via Benzinga
News headline image
Lineage Cell Revenue Doubles in Q2 ↗
Via The Motley Fool
News headline image
Lineage Cell Therapeutics Inc. (NYSEARCA:LCTX) Reports Q2 2025 Revenue Beat but Wider Loss ↗
Lineage Cell Therapeutics Q2 2025: Revenue beats estimates at $2.77M (+84.6%), but net loss widens to -$0.13. Stock dips 4.95% amid clinical progress and cash runway into 2027. 
Via Chartmill
News headline image
Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Earnings Scheduled For August 12, 2025 ↗
 
Via Benzinga
News headline image
Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Two Biotech Stocks Poised For Big Moves On Monday ↗
 
Via Benzinga
News headline image
OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Examining the Future: Lineage Cell Therapeutics's Earnings Outlook ↗
 
Via Benzinga
News headline image
Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Earnings Scheduled For May 13, 2025 ↗
 
Via Benzinga
News headline image
RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Which stocks are moving after the closing bell on Wednesday? ↗
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
News headline image
Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Earnings Scheduled For March 10, 2025 ↗
 
Via Benzinga
News headline image
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury
From Lineage Cell Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >